{"id":"NCT01880424","sponsor":"AstraZeneca","briefTitle":"A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)","officialTitle":"A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-07","primaryCompletion":"2015-05","completion":"2015-05","firstPosted":"2013-06-19","resultsPosted":"2016-09-27","lastUpdate":"2016-09-27"},"enrollment":1722,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Irritable Bowel Syndrome With Constipation (IBS-C)"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Linaclotide","otherNames":[]}],"arms":[{"label":"controlled arm","type":"PLACEBO_COMPARATOR"},{"label":"treatment arm","type":"EXPERIMENTAL"}],"summary":"This clinical trial is an international, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial comparing one dose of linaclotide to placebo. Approximately 800 patients with a diagnosis of IBS-C (modified Rome III criteria) will be randomized at up to 60 trial centers in China, Australia, and New Zealand.\n\nThe trial will consist of up to 21 days of screening, 14 to 21 days of pre-treatment, 12 weeks of double-blind treatment, and 2 weeks of follow-up. At the end of the Pre-treatment Period, patients meeting the entry criteria for this trial will be randomized to one of two double-blind treatment groups: 290 ug linaclotide, or placebo (1:1).","primaryOutcome":{"measure":"12-week Abdominal Pain/Abdominal Discomfort Weekly Responder","timeFrame":"Baseline and Weeks 1-12 during the Treatment Period","effectByArm":[{"arm":"Linaclotide Arm","deltaMin":250,"sd":null},{"arm":"Placebo Arm","deltaMin":206,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0010"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":82,"countries":["United States","Australia","Canada","China","New Zealand"]},"refs":{"pmids":["35019221"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":416},"commonTop":["Diarrhea","Upper respiratory tract infection"]}}